Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company whose news flow centers on gastrointestinal diseases, infectious diseases and oncology. Company press releases furnished on Form 6-K highlight both commercial developments around its FDA-approved H. pylori therapy Talicia® and clinical and preclinical updates from its late-stage pipeline, including opaganib (ABC294640), RHB-102 (Bekinda®), RHB-204 and RHB-107 (upamostat).
Investors following RDHL news can expect regular updates on Talicia’s commercialization, such as U.S. co-commercialization with Cumberland Pharmaceuticals, ex-U.S. licensing deals in regions like the Middle East, and milestone and royalty payments from international launches. RedHill also issues news on Talicia’s clinical positioning, including its status as a first-line option in American College of Gastroenterology guidelines and its role as a low-dose rifabutin-based therapy designed to address H. pylori antibiotic resistance.
On the development side, RedHill’s news frequently covers pipeline data and regulatory plans. Examples include positive in vivo and clinical results for opaganib in oncology and viral indications, Phase 2 and Phase 3 outcomes for RHB-102 in gastroenteritis, gastritis and IBS-D, and plans for RHB-102 in GLP-1/GIP receptor agonist therapy-associated gastrointestinal side effects. Updates also describe RHB-107’s late-stage development in non-hospitalized symptomatic COVID-19 and RHB-204’s planned studies in Crohn’s disease and pulmonary nontuberculous mycobacteria disease.
RedHill’s news feed additionally reports on Nasdaq listing compliance matters, capital-raising activities, and legal proceedings, such as New York Supreme Court judgments and related enforcement steps in the Kukbo litigation. For readers tracking RDHL, this page aggregates these corporate, clinical, regulatory and legal announcements in one place, allowing a consolidated view of the company’s ongoing activities and disclosures.
RedHill Biopharma (Nasdaq: RDHL) has announced the issuance of a new U.S. patent for opaganib, valid through 2041. The patent covers the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19.
Post-hoc data from opaganib's Phase 2/3 study showed that patients with ≤60% FiO2 levels had better outcomes after 14 days of treatment compared to placebo, including:
- Increased number of patients no longer requiring supplemental oxygen (76.9% vs. 63.4%; p-value=0.033)
- 62.6% reduction in intubation/mechanical ventilation (6.84% vs. 17.91%; p-value=0.012)
- 62% reduction in mortality by day 42 (5.98% vs. 16.7%; p-value=0.019)
Opaganib is being developed for various indications, including oncology, viral infections, inflammatory diseases, and nuclear/radioprotection.
RedHill Biopharma (Nasdaq: RDHL) announced that its product Talicia® has been listed as a first-line choice for treating H. pylori infection in the new American College of Gastroenterology (ACG) Clinical Guideline. This is significant as it's the first update since Talicia's approval. Talicia offers a convenient all-in-one formulation taken three times daily, supporting high eradication rates without prior resistance testing.
Talicia is currently the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori, which affects about 35% of U.S. adults. Globally, H. pylori infects around 66% of the population and is classified as a Group 1 carcinogen by the WHO, being the strongest known risk factor for gastric cancer.
RedHill Biopharma (Nasdaq: RDHL) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from the Nasdaq Listings Qualifications Department that it has met the necessary criteria for continued listing on The Nasdaq Capital Market. To achieve compliance, RedHill was required to maintain a minimum closing bid price of $1.00 per share for its American Depositary Shares (ADSs) for at least 10 consecutive business days. This milestone was reached on September 3, 2024, ensuring RedHill's continued presence on the Nasdaq exchange.
RedHill Biopharma (Nasdaq: RDHL) has announced the publication of data from a post-hoc analysis of its phase 2/3 study of opaganib in COVID-19 pneumonia. The analysis, published in the journal Microorganisms, showed a 62% reduction in mortality and a 21% improvement in time to room air in a subgroup of 251 hospitalized patients requiring FiO2 ≤60%. The study also suggests that FiO2 >60% may represent a threshold for disease severity and could potentially serve as a patient selection biomarker. With 30,000 Americans dead due to COVID-19 so far this year, RedHill emphasizes the continued need for effective and safe therapies. Opaganib, an orally administered drug, has demonstrated safety and efficacy profiles in various indications, including viral infections and inflammatory diseases.
RedHill Biopharma (Nasdaq: RDHL) reported its first half 2024 financial results and operational highlights. The company has transformed with a strengthened cash balance, streamlined operations, and a focus on U.S. government collaborations for developing its pipeline. Key highlights include:
- Cash balance of $8.2 million as of June 30, 2024
- Net revenues of $2.6 million for H1 2024
- Talicia maintained leadership position as the top prescribed branded H. pylori therapy in the U.S.
- Advancing opaganib and RHB-107 in U.S. government-supported programs for various indications including Ebola, COVID-19, and radiation protection
- Cost reduction measures resulted in improved operating loss and net loss compared to H1 2023
- Post-balance sheet, RedHill signed a Global Termination Agreement, receiving $9.9 million in cash and reducing net liabilities by approximately $2.3 million
RedHill Biopharma (Nasdaq: RDHL) has announced that the FDA has granted orphan-drug designation to opaganib for the treatment of neuroblastoma, a rare childhood cancer. This designation provides seven years of marketing exclusivity if approved and may offer additional benefits such as accelerated development and review times, potential grant funding, and tax credits.
Neuroblastoma accounts for up to 10% of childhood cancer cases and 15% of pediatric cancer-related deaths in the U.S. The neuroblastoma market is expected to reach nearly $1.5 billion before the mid-2030s. This is the second orphan drug designation for opaganib in oncology, following its designation for cholangiocarcinoma. Opaganib is being developed for multiple indications, including COVID-19, Ebola, and acute respiratory distress syndrome.
RedHill Biopharma has launched Talicia, the first approved low-dose rifabutin-containing combination treatment for H. pylori, in the United Arab Emirates (UAE). This launch triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments, and tiered royalties up to mid-teens on net sales.
Talicia is now available by prescription to treat adults with H. pylori infection in the UAE, where 41% of the population is affected. The drug is designed to address the declining effectiveness of clarithromycin-based therapies, which have shown eradication rates as low as 32% in patients with resistant H. pylori strains.
As the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori treatment, Talicia's launch in the UAE represents a significant step in addressing this major public health concern and expanding RedHill's global market presence.
RedHill Biopharma (Nasdaq: RDHL) has announced positive results from multiple in vivo studies showing the impact of opaganib, a sphingosine kinase-2 (SPHK2) inhibitor, on weight gain and glucose tolerance in a high fat diet (HFD) model. The studies support the potential clinical use of opaganib for the prevention and therapy of Type 2 diabetes and other obesity-related disorders.
Opaganib's ability to modulate multiple signaling pathways through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells provides a strong rationale for its evaluation in obesity-related disorders. The studies showed that opaganib therapy suppressed HFD-induced body weight gain, loss of glucose tolerance, and fat deposition. It also reduced weight gain and restored glucose tolerance in an already obese HFD model.
The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034, driven by GLP-1 inhibitors and SGLT2 inhibitors.
RedHill Biopharma (Nasdaq: RDHL) has announced plans to implement a ratio change for its American Depositary Shares (ADSs) on August 20, 2024. The new ratio will be 1 ADS representing 10,000 ordinary shares, compared to the current 1:400 ratio. This change will effectively result in a 1-for-25 reverse ADS split.
The company's ADSs will continue trading on the Nasdaq Capital Market under the symbol 'RDHL' with a new CUSIP Number. No new ADSs will be issued, and existing ADS holders will have their holdings automatically exchanged. Fractional new ADSs will be sold, with proceeds distributed to applicable holders.
This move aims to address RedHill's non-compliance with Nasdaq's minimum bid price requirements, as notified on March 14, 2024. While the company anticipates the ADS price will increase proportionally to meet Nasdaq's requirements, there is no guarantee of this outcome.
RedHill Biopharma (Nasdaq: RDHL) has announced positive Phase 3 data for RHB-104, a triple antimicrobial therapy targeting Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease. The study, published in the journal Antibiotics, showed that RHB-104 plus standard of care (SoC) was 64% more effective than SoC alone. The primary endpoint of clinical remission at week 26 was achieved in 36.7% of RHB-104 patients compared to 22.4% of placebo patients (p=0.0048). The safety profile was similar to placebo. This data supports the hypothesis of a Mycobacterial basis for Crohn's disease and opens a potential new avenue for treatment. The Crohn's disease market was valued at over $13 billion in 2023.